Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.38 |
| ▸ | LSS | P48449 | 1/20 | 0.36 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.32 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578423 | 0.80 | QDPR (0.44) | QDPRLSS | |
| SCHEMBL9947231 | 0.79 | NAMPT (0.47) | — | |
| SCHEMBL11961065 | 0.78 | MAPT (0.41) | ESR2 | |
| SCHEMBL13474635 | 0.78 | LPL (0.38) | — | |
| SCHEMBL12597610 | 0.77 | HDAC4 (0.44) | BRD9HDAC4HDAC1HDAC6 | |
| SCHEMBL1911717 | 0.75 | LMNA (0.46) | HDAC6 | |
| SCHEMBL13509394 | 0.75 | LPL (0.34) | — | |
| SCHEMBL14316224 | 0.73 | ATM (0.48) | APOBEC3AAPOBEC3G | |
| SCHEMBL902510 | 0.73 | DGAT1 (0.39) | — | |
| SCHEMBL13195897 | 0.73 | DGAT1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149686-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORKS (CA) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149686-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | MAP3K5, MAP3K6, MAP3K1 | QDPR 1469/4885LSS 2629/4885BRD9 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.